AMENDMENT

In the Claims:

The following listing reflects the currently pending claims and replaces all prior versions and listings of claims in this application. No amendments have been made herein.

1. (Previously presented) A composition comprising an hyaluronic acid ester polymer in the form of a microsphere, a detoxified mutant of a bacterial ADP-ribosylating toxin, and a selected antigen, wherein said antigen is present in an amount of approximately .1% to about 40% (w/w) antigen to hyaluronic acid polymer, and wherein the antigen is not entrapped in the microsphere.

2. (Original) The composition of claim 1, wherein said antigen is present in an amount of approximately 2% to about 25% (w/w) antigen to hyaluronic acid polymer.

3. (Original) The composition of claim 1, wherein the hyaluronic acid ester is selected from the group consisting of an hyaluronic acid where from about 75% to about 100% of free carboxyl groups are esterified with one or more alkyl groups, and a crosslinked derivative of hyaluronic acid in which about 0.5% to about 20% of the carboxyl groups of the hyaluronic acid polymer are crosslinked to hydroxyl groups of the same or a different hyaluronic acid molecule.

4. (Cancelled)

5. (Previously presented) The composition of claim 1, wherein the detoxified mutant of a bacterial ADP-ribosylating toxin selected from the group consisting of LT-K63 and LT-R72.

6. (Original) The composition of claim 1, wherein the selected antigen is a viral antigen.

7. (Original) The composition of claim 6, wherein the selected antigen is an influenza antigen.

8-10. (Cancelled)

11. (Previously presented) A composition comprising (a) a microsphere comprised of an hyaluronic acid ester polymer selected from the group consisting of an hyaluronic acid where from about 75% to about 100% of free carboxyl groups are esterified with one or more alkyl groups, and a crosslinked derivative of hyaluronic acid in which about 0.5% to about 20% of the carboxyl groups of the hyaluronic acid polymer are crosslinked to hydroxyl groups of the same or a different hyaluronic acid molecule; (b) a selected antigen adsorbed to the microsphere, wherein said antigen is present in an amount of approximately 2% to about 25% (w/w) antigen to hyaluronic acid polymer; and (c) an immunological adjuvant.

12-13. (Cancelled)

14. (Original) A method of making a pharmaceutical composition which comprises combining the composition of claim 1 with a pharmaceutically acceptable mucosal excipient.

15. (Original) A method of making a pharmaceutical composition which comprises combining the composition of claim 11 with a pharmaceutically acceptable mucosal excipient.

16. (Original) A method of immunization which comprises mucosally administering a therapeutically effective amount of the pharmaceutical composition of claim 14 to a vertebrate subject.

17. (Original) A method of immunization which comprises mucosally administering a therapeutically effective amount of the pharmaceutical composition of claim 15 to a vertebrate subject.

18. (Original) The method of claim 16 wherein the administering is done intranasally.

19. (Original) The method of claim 17 wherein the administering is done intranasally.

20. (Cancelled)

21. (Previously presented) The composition of claim 1, wherein the microsphere is a nanosphere.

22. (Previously presented) The composition of claim 11, wherein the microsphere is a nanosphere.